J. Scheiber

发表

Andreas Bender, Meir Glick, Jeremy L. Jenkins, 2009, J. Chem. Inf. Model..

Which aspects of HTS are empirically correlated with downstream success?

Thomas J. Crisman, Z. Deng, A. Bender, 2008, Current opinion in drug discovery & development.

Mapping adverse drug reactions in chemical space.

M. Milik, A. Bender, J. Jenkins, 2009, Journal of medicinal chemistry.

Use of ligand based models for protein domains to predict novel molecular targets and applications to triage affinity chromatography data.

John A. Tallarico, A. Bender, J. Jenkins, 2009, Journal of proteome research.

Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure

A. Bender, J. Jenkins, J. Scheiber, 2007, ChemMedChem.

SPREAD—exploiting chemical features that cause differential activity behavior

Andreas Bender, Meir Glick, Ben Cornett, 2009 .

Plate-Based Diversity Selection Based on Empirical HTS Data to Enhance the Number of Hits and Their Chemical Diversity

Andreas Bender, Meir Glick, Dmitri Mikhailov, 2009, Journal of biomolecular screening.

How can we enable drug discovery informatics for personalized healthcare?

Josef Scheiber, J. Scheiber, 2011, Expert opinion on drug discovery.

Knowledge‐Based and Computational Approaches to In Vitro Safety Pharmacology

Andreas Bender, Jeremy L. Jenkins, Kamal Azzaoui, 2009 .

Charge interactions do the job: a combined statistical and combinatorial approach to finding artificial receptors for binding tetrapeptides in water.

J. Scheiber, K. Baumann, C. Schmuck, 2005, Angewandte Chemie.

Understanding False Positives in Reporter Gene Assays: in Silico Chemogenomics Approaches To Prioritize Cell-Based HTS Data

Andreas Bender, Meir Glick, Jeremy L. Jenkins, 2007, J. Chem. Inf. Model..

Interaction of (benzylidene-hydrazono)-1,4-dihydropyridines with beta-amyloid, acetylcholine, and butyrylcholine esterases.

J. Scheiber, U. Holzgrabe, B. Engels, 2010, Bioorganic & medicinal chemistry.

Cover Picture: Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off-Target Effects from Chemical Structure (ChemMedChem 6/2007)

A. Bender, J. Jenkins, J. Scheiber, 2007 .

Rare SARS-CoV-2 antibody development in cancer patients

J. Scheiber, V. Milani, Željka Trepotec, 2020, Seminars in Oncology.

Backtranslating clinical knowledge for use in cheminformatics--what is the potential?

J. Scheiber, 2012, Bioorganic & medicinal chemistry.

Cis‐Configured Aziridines Are New Pseudo‐Irreversible Dual‐Mode Inhibitors of Candida albicans Secreted Aspartic Protease 2

Sebastian G. Rohrer, J. Scheiber, K. Baumann, 2008, ChemMedChem.

Targeting acetylcholinesterase to treat neurodegeneration

Vildan Alptüzün, Ulrike Holzgrabe, Josef Scheiber, 2007, Expert opinion on therapeutic targets.

Aziridide‐Based Inhibitors of Cathepsin L: Synthesis, Inhibition Activity, and Docking Studies

J. Scheiber, N. Stiefl, K. Baumann, 2006, ChemMedChem.

NMR Spectroscopic and Molecular Modelling Studies on Cyclodextrin–Dipeptide Inclusion Complexes

J. Scheiber, U. Holzgrabe, K. Baumann, 2005 .

Comparison of Cyclodextrin‐Dipeptide Inclusion Complexes in the Absence and Presence of Urea by Means of Capillary Electrophoresis, Nuclear Magnetic Resonance and Molecular Modeling

Knut Baumann, Ulrike Holzgrabe, Josef Scheiber, 2007 .

Omics and Artificial Intelligence in Kidney Diseases.

Han Zhang, J. Scheiber, N. Grobe, 2023, Advances in kidney disease and health.

A new promising oncogenic target (p.C382R) for treatment with pemigatinib in patients with cholangiocarcinoma

J. Scheiber, P. Philipp, A. Gaumann, 2022, Therapeutic advances in medical oncology.

Bridging Chemical and Biological Data: Implications for Pharmaceutical Drug Discovery

Ben Cornett, Jeremy L. Jenkins, Andreas Bender, 2011 .

SARS‐CoV‐2 infections in cancer outpatients—Most infected patients are asymptomatic carriers without impact on chemotherapy

J. Scheiber, F. Ebner, M. Pfaffl, 2020, Cancer medicine.

Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis

Bin Chen, Andreas Bender, Meir Glick, 2009, J. Chem. Inf. Model..

Detection of acquired resistance mutation ALK G1202R after treatment with alectinib and response of lorlatinib

J. Scheiber, A. Gaumann, A. Kleespies, 2021, memo - Magazine of European Medical Oncology.

xMaP - An Interpretable Alignment-Free Four-Dimensional Quantitative Structure-Activity Relationship Technique Based on Molecular Surface Properties and Conformer Ensembles

Josef Scheiber, Jan Dreher, Knut Baumann, 2018, J. Chem. Inf. Model..

How to Implement Safe, Efficient and Cost-Effective SARS-CoV-2 Testing in Urban and Rural Schools within One Month

J. Scheiber, A. Burkovski, P. Pagel, 2021, COVID.

"Virtual fragment linking": an approach to identify potent binders from low affinity fragment hits.

Andreas Bender, Meir Glick, Mariusz Milik, 2008, Journal of medicinal chemistry.

Chemogenomic analysis of safety profiling data.

Jeremy L Jenkins, Josef Scheiber, J. Jenkins, 2009, Methods in molecular biology.